$SLDB
Solid Biosciences Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096130 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $27.33M $19.46M
YoY Change 63.62% -1.6%
% of Gross Profit
Depreciation & Amortization $405.0K $1.235M
YoY Change -31.12% 75.68%
% of Gross Profit
Operating Expenses $35.18M $27.79M
YoY Change 52.21% 3.52%
Operating Profit -$35.18M -$27.79M
YoY Change 52.21% 3.52%
Interest Expense $88.00K
YoY Change -95.48%
% of Operating Profit
Other Income/Expense, Net $2.457M $2.716M
YoY Change 15.14% 22.67%
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$32.73M -$25.07M
YoY Change 55.98% 1.8%
Net Earnings / Revenue
Basic Earnings Per Share -$0.79 -$0.61
Diluted Earnings Per Share -$0.79 -$0.61
COMMON SHARES
Basic Shares Outstanding 38.60M 38.38M
Diluted Shares Outstanding 41.44M 40.93M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $171.1M $190.3M
YoY Change 19.76% 18.77%
Cash & Equivalents $64.39M $95.85M
Short-Term Investments $106.7M $94.41M
Other Short-Term Assets $8.377M $7.344M
YoY Change 52.31% 0.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $179.5M $197.6M
YoY Change 21.0% 17.99%
LONG-TERM ASSETS
Property, Plant & Equipment $5.067M $5.438M
YoY Change -28.08% -26.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $475.0K $515.0K
YoY Change 50.79% 184.53%
Total Long-Term Assets $32.33M $33.37M
YoY Change -11.13% -10.4%
TOTAL ASSETS
Total Short-Term Assets $179.5M $197.6M
Total Long-Term Assets $32.33M $33.37M
Total Assets $211.8M $231.0M
YoY Change 14.67% 12.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.458M $2.521M
YoY Change 82.19% -15.06%
Accrued Expenses $13.23M $9.918M
YoY Change 15.36% -5.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.051M $525.0K
YoY Change 162.75% 25.3%
Total Short-Term Liabilities $22.85M $14.69M
YoY Change 44.5% -7.42%
LONG-TERM LIABILITIES
Long-Term Debt $307.0K $953.0K
YoY Change -78.07% -35.7%
Other Long-Term Liabilities $21.64M $22.10M
YoY Change -6.71% -6.56%
Total Long-Term Liabilities $21.95M $23.05M
YoY Change -10.77% -8.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.85M $14.69M
Total Long-Term Liabilities $21.95M $23.05M
Total Liabilities $44.80M $37.74M
YoY Change 10.99% -7.95%
SHAREHOLDERS EQUITY
Retained Earnings -$740.9M -$708.1M
YoY Change 16.05% 14.68%
Common Stock $907.8M $901.4M
YoY Change 15.97% 15.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $167.0M $193.2M
YoY Change
Total Liabilities & Shareholders Equity $211.8M $231.0M
YoY Change 14.67% 12.83%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$32.73M -$25.07M
YoY Change 55.98% 1.8%
Depreciation, Depletion And Amortization $405.0K $1.235M
YoY Change -31.12% 75.68%
Cash From Operating Activities -$23.71M -$21.47M
YoY Change 32.45% -21.84%
INVESTING ACTIVITIES
Capital Expenditures $15.00K $286.0K
YoY Change -96.15% -46.64%
Acquisitions
YoY Change
Other Investing Activities -$10.97M -$4.890M
YoY Change -54.75% -89.75%
Cash From Investing Activities -$10.99M -$5.176M
YoY Change -55.41% -89.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.256M 5.000M
YoY Change 91.06%
NET CHANGE
Cash From Operating Activities -23.71M -21.47M
Cash From Investing Activities -10.99M -5.176M
Cash From Financing Activities 3.256M 5.000M
Net Change In Cash -31.44M -21.64M
YoY Change -26.1% -70.38%
FREE CASH FLOW
Cash From Operating Activities -$23.71M -$21.47M
Capital Expenditures $15.00K $286.0K
Free Cash Flow -$23.72M -$21.75M
YoY Change 29.7% -22.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001707502
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38360
dei Entity Registrant Name
EntityRegistrantName
Solid Biosciences Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0943402
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Rutherford Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Third FloorCharlestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
337-4680
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
SLDB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38595237
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95854000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74015000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
94412000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
49625000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7344000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6094000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
197610000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
129734000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25508000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26539000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5438000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6624000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
515000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
209000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1910000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
33371000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
35205000
CY2024Q2 us-gaap Assets
Assets
230981000
CY2023Q4 us-gaap Assets
Assets
164939000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2521000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2032000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9918000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10161000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1724000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1855000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
525000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
469000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14688000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14517000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22095000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22707000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
953000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1234000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
23048000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
23941000
CY2024Q2 us-gaap Liabilities
Liabilities
37736000
CY2023Q4 us-gaap Liabilities
Liabilities
38458000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38551059
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38551059
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20386606
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20386606
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
39000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
901349000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
785199000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-708128000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-658753000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
193245000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
126481000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230981000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164939000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19461000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19777000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38334000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44408000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8327000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7129000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16316000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14528000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
-63000
us-gaap Restructuring Charges
RestructuringCharges
-63000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
27788000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
26843000
us-gaap Operating Expenses
OperatingExpenses
54650000
us-gaap Operating Expenses
OperatingExpenses
58873000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27788000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26843000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54650000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58873000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2565000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2060000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5216000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3860000
CY2024Q2 us-gaap Interest Expense
InterestExpense
88000
CY2023Q2 us-gaap Interest Expense
InterestExpense
111000
us-gaap Interest Expense
InterestExpense
183000
us-gaap Interest Expense
InterestExpense
233000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
239000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
265000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
242000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
547000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2716000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2214000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5275000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4174000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-25072000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
us-gaap Profit Loss
ProfitLoss
-49375000
us-gaap Profit Loss
ProfitLoss
-54699000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40934361
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40934361
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19663672
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19663672
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39544867
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39544867
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19618517
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19618517
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-25072000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
us-gaap Profit Loss
ProfitLoss
-49375000
us-gaap Profit Loss
ProfitLoss
-54699000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
82000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25083000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24620000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-49405000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-54617000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
126481000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1611000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4407000
CY2024Q1 sldb Adjustments To Additional Paid In Capital Pre Funded Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts
704000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14293000
CY2024Q1 sldb Adjustments To Additional Paid In Capital Net Of Sales Commissions
AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
78000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3056000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
151000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24303000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
210724000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2092000
CY2024Q2 sldb Adjustments To Additional Paid In Capital Net Of Sales Commissions
AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
138000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5357000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
145000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-25072000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
193245000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
211666000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2118000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
183787000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1944000
CY2023Q2 sldb Adjustments To Additional Paid In Capital Net Of Sales Commissions
AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
65000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2539000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
78000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
163728000
us-gaap Profit Loss
ProfitLoss
-49375000
us-gaap Profit Loss
ProfitLoss
-54699000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1581000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
273000
us-gaap Share Based Compensation
ShareBasedCompensation
3703000
us-gaap Share Based Compensation
ShareBasedCompensation
4062000
sldb Depreciation Impairment And Amortization Expense
DepreciationImpairmentAndAmortizationExpense
1562000
sldb Depreciation Impairment And Amortization Expense
DepreciationImpairmentAndAmortizationExpense
1780000
sldb Non Cash Lease Expense
NonCashLeaseExpense
1241000
sldb Non Cash Lease Expense
NonCashLeaseExpense
1247000
us-gaap Other Noncash Income
OtherNoncashIncome
94000
us-gaap Other Noncash Income
OtherNoncashIncome
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1556000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
563000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
472000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-864000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-817000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-167000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6228000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46659000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55460000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
435000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1042000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-60300000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-58632000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
103536000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68562000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43666000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10972000
sldb Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
108858000
sldb Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5111000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
sldb Proceeds From Issuance Of Common Stock In Public Offering Net Of Sales Commissions
ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions
8414000
sldb Proceeds From Issuance Of Common Stock In Public Offering Net Of Sales Commissions
ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions
2539000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
160000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
145000
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
78000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
225000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112241000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2617000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21916000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-63815000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75848000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157217000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97764000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93402000
us-gaap Interest Paid Net
InterestPaidNet
183000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
407000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
139000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-197000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-252000
sldb Increase Decrease In Property Plant And Equipment Due To Asset Exchange
IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange
0
sldb Increase Decrease In Property Plant And Equipment Due To Asset Exchange
IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange
-950000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
141000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95854000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91569000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1910000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97764000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93402000
sldb Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-708100000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-25100000
us-gaap Profit Loss
ProfitLoss
-49400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46700000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
190300000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
1900000
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
61383000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94412000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
155795000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
62398000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49625000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112023000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
94427000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94412000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49610000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49625000
sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y4M24D
CY2023 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y4M24D
CY2024Q2 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
5221000
CY2023Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
3980000
CY2024Q2 sldb Prepaid Other And Other Current Assets
PrepaidOtherAndOtherCurrentAssets
2123000
CY2023Q4 sldb Prepaid Other And Other Current Assets
PrepaidOtherAndOtherCurrentAssets
2114000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7344000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6094000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9918000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10161000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2092000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1944000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3703000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4062000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2259672
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1119522
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26342
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
41659
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
24.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
421148
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.98
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2890045
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2890045
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M25D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
998150
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
39.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M
CY2024Q2 sldb Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
7.51
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.229
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.22
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.287
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.229
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.287
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.218
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.296
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.044
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.52
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.08
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
300000
us-gaap Sublease Income
SubleaseIncome
500000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
300000
us-gaap Sublease Income
SubleaseIncome
500000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-25072000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
us-gaap Profit Loss
ProfitLoss
-49375000
us-gaap Profit Loss
ProfitLoss
-54699000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40934361
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40934361
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19663672
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19663672
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39544867
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39544867
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19618517
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19618517
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
CY2024Q2 sldb Common Stock Issuable Upon Exercise Of Prefunded Warrants
CommonStockIssuableUponExerciseOfPrefundedWarrants
2712478
sldb Common Stock Issuable Upon Exercise Of Prefunded Warrants
CommonStockIssuableUponExerciseOfPrefundedWarrants
2712478
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6711851
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6711851
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3193408
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3193408
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-096130-index-headers.html Edgar Link pending
0000950170-24-096130-index.html Edgar Link pending
0000950170-24-096130.txt Edgar Link pending
0000950170-24-096130-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img246672473_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-20240630.htm Edgar Link pending
sldb-20240630.xsd Edgar Link pending
sldb-ex31_1.htm Edgar Link pending
sldb-ex31_2.htm Edgar Link pending
sldb-ex32_1.htm Edgar Link pending
sldb-ex32_2.htm Edgar Link pending
sldb-20240630_htm.xml Edgar Link completed